Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585644 | 0.90 | PTGDR2 (0.67) | PTGDR2TDP1TSHR | |
| SCHEMBL1333288 | 0.89 | PTGDR2 (0.56) | PTGDR2TDP1TSHR | |
| SCHEMBL1333312 | 0.86 | PTGDR2 (0.70) | PTGDR2 | |
| SCHEMBL4015627 | 0.83 | PTGDR2 (0.55) | PTGDR2TSHRPTGDR | |
| SCHEMBL1333641 | 0.83 | PTGDR2 (0.55) | PTGDR2TSHRPTGDR | |
| SCHEMBL1332090 | 0.83 | PTGDR2 (0.51) | PTGDR2ALDH1A1 | |
| SCHEMBL1690330 | 0.81 | PTGDR2 (1.00) | PTGDR2TDP1TSHRAKR1B1PTGDR | |
| SCHEMBL1332548 | 0.81 | PTGDR2 (0.71) | PTGDR2TDP1TSHRAKR1B1PTGDR | |
| SCHEMBL1332152 | 0.79 | PTGDR2 (0.55) | PTGDR2 | |
| SCHEMBL2396290 | 0.79 | PTGDR2 (0.46) | PTGDR2TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394986-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (GB) | 2013-03-12 | — | — | US | claimed |
| US-20110281898-A1 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB | 2011-11-17 | — | — | US | claimed |
| EP-1660431-B1 | PHENOXYACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2009-04-01 | — | — | EP | claimed |
| JP-2007502806-A | — | — | 2007-02-15 | — | — | JP | claimed |
| US-20060293352-A1 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | claimed |
| EP-1660431-A2 | PHENOXYACETIC ACID DERIVATIVES | Astrazeneca AB (SE) | 2006-05-31 | — | — | EP | claimed |
| WO-2005018529-A2 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | claimed |
| US-8394986-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (GB) | 2013-03-12 | — | — | US | disclosed |
| US-8394986-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20110281898-A1 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB | 2011-11-17 | — | — | US | disclosed |
| US-20110281898-A1 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB | 2011-11-17 | — | — | US | disclosed |
| US-8003703-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| US-8003703-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| US-8003703-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| EP-1660431-B1 | PHENOXYACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| US-20060293352-A1 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| EP-1660431-A2 | PHENOXYACETIC ACID DERIVATIVES | Astrazeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005018529-A2 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293352-A1 | Phenoxiacetic acid derivatives | HRH2, HRH1, HCAR2 | PTGDR2 13/4885TDP1 4078/4885TSHR 655/4885 |
| US-20110281898-A1 | PHENOXIACETIC ACID DERIVATIVES | HIF1A, HPD, HIF1AN | PTGDR2 256/4885TDP1 3242/4885TSHR 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.